\section*{ABSTRACT}

The early occurrence of \(\beta\)-cell dysfunction has been broadly recognized as a critical determinant of the development and progression of type 2 diabetes. \(\beta\)-cell dysfunction might be induced by insufficient \(\beta\)-cell mass, by a dysfunction of the \(\beta\)-cells, or both. Whether or not \(\beta\)-cell dysfunction constitutes a cause of reduced \(\beta\)-cells or vice-versa currently remains unclear. The results of some studies have measured the loss of \(\beta\)-cells in type 2 diabetic patients at between 22 and 63\% by planimetric measurements. Because \(\beta\)-cell hypertrophy has been noted in type 2 diabetic patients, the loss of \(\beta\)-cell number should prove more profound than what has thus far been reported. Furthermore, \(\beta\)-cell volumes are reduced even in patients with impaired fasting glucose. Such defects in \(\beta\)-cell mass are associated with increased apoptosis rather than insufficient replication or neogenesis of \(\beta\)-cells. With these results, although they still require clarification, the peak \(\beta\)-cell mass might be determined at quite an early stage of life, and then might decline progressively over time as the result of exposure to harmful environmental influences over one's lifetime. In this review, we have summarized the relevant studies regarding \(\beta\)-cell mass in patients with type 2 diabetes, and then presented a review of the various causes of \(\beta\)-cell loss in adults. (\textit{J Diabetes Invest}, doi: 10.1111/j.2040-1124.2010.00072.x, 2010)

\section*{KEY WORDS:} Diabetes, \(\beta\)-cell mass, Hypertrophy

\section*{INTRODUCTION}

Type 2 diabetes is the most common form of diabetes in humans. In the past few decades, the global incidence and prevalence of diabetes has increased dramatically. Additionally, the number of people with diabetes is expected to exceed 350 million individuals in 2025\textsuperscript{5}. Even in only one country, China\textsuperscript{2}, the number of diabetic patients has recently approached 90 million individuals, and a comparable number of patients also exists in another Asian countries – namely, India\textsuperscript{3}. The increase in type 2 diabetes in Asia differs from that reported in other regions of the world; it has evolved over a much shorter time, in a younger age group and in people with substantially lower body mass indices (BMI)\textsuperscript{4}. Because the degree of obesity and aging is closely related to the degree of insulin resistance, insulin secretory defects might carry out a more important function in the development and progression of diabetes in our region.

\(\beta\)-cell dysfunction might be induced by the loss of \(\beta\)-cell mass, by functional defects in \(\beta\)-cells, or both. Reductions in \(\beta\)-cell mass and \(\beta\)-cell dysfunction have both been shown in patients with type 2 diabetes\textsuperscript{5}. Whether or not \(\beta\)-cell dysfunction is the cause of reduced \(\beta\)-cell mass or vice-versa remains to be determined. We will focus on the \(\beta\)-cell mass of people with type 2 diabetes.

A genetic element clearly underlies \(\beta\)-cell dysfunction and insufficient \(\beta\)-cell mass; however, a number of modifiable factors are also linked to \(\beta\)-cell deterioration, most notably chronic hyperglycemia and elevated free fatty acid (FFA) levels. Evidence has also been found for a link between increased pro-inflammatory cytokines and the impairment of insulin-signaling pathways in the \(\beta\)-cells, as well as the potential roles of islet amyloid deposition and fibrotic islet destruction.

In the present review, we provide an overview of the characteristic features and underlying pathogenesis of \(\beta\)-cell mass defects in patients with type 2 diabetes mellitus, and then describe the morphological characteristics of the pancreatic islets. Finally, we address the pathogenic mechanisms and possible clinical implications of preventing \(\beta\)-cell mass destruction in the prevention and delay of the progression of this disease.

\section*{\(\beta\)-CELL MASS: FACTS AND UNRESOLVED QUESTIONS}

\subsection*{\(\beta\)-Cell Mass in Diabetic Patients}

\(\beta\)-cell mass is determined as the sum of replication, neogenesis and hypertrophy minus the rate of apoptosis. Normally, obesity, pregnancy and increases in insulin resistance are the principal causes of \(\beta\)-cell mass increases, through enhanced replication, neogenesis and hypertrophy. However, the progression from an insulin resistance condition to diabetes is inevitably associated with \(\beta\)-cell dysfunction and reduced \(\beta\)-cell mass\textsuperscript{5,6}. Many previous studies have reported that \(\beta\)-cell mass in type 2 diabetic subjects tends to be reduced relative to normal subjects. Saito \textit{et al.}\textsuperscript{7} reported previously that the total islet number was approximately 30\% lower in subjects with type 2 diabetes relative to the non-diabetic subjects. In the same year, Westermark and Wilander\textsuperscript{8} also noted a 30\% reduction in the total islet volumes...
of diabetic subjects. The islet volume of the diabetic patients was 1.01 ± 0.12 cm³ and that of the non-diabetic patients was 1.60 ± 0.16 cm³. In 2002, Sakuraba et al.² measured a 22–30% reduction in β-cell volume, as well as a 22% reduction in the quantity of islets in Japanese type 2 diabetic patients. In 2003, Butler et al. reported that obese humans with type 2 diabetes evidenced a 63% deficit in relative β-cell volume relative to non-diabetic obese subjects, although the relative β-cell volumes were increased in obese vs lean non-diabetic cases. Lean subjects with type 2 diabetes also evidenced a 41% deficit in relative β-cell volumes. In 2003, we also showed that β-cell mass was reduced in Korean type 2 diabetic patients. The mean relative volume of β-cells was reduced by approximately 50% relative to normal subjects (Figure 1). Recently, Rahier et al. clearly showed that β-cell mass decreased by approximately 39%, occurring similarly in the body and tail of the pancreatic islets in European subjects with type 2 diabetes. All together, we could agree that 30–60% of β-cell mass was decreased in patients with type 2 diabetes mellitus and we also observed unexpected broad heterogeneity of β-cell mass in each patient in many studies.

Interestingly, a good linear correlation between β-cell mass and BMI has been reported in normal subjects and type 2 diabetic patients, as well by our group, and such a trend was also reproduced by another group. These results suggest appropriate β-cell mass is critically important to maintain a certain amount of body mass in normal subjects and diabetic patients as well.

The evidence for β-cell regeneration after various pancreatic injuries occurring in humans is minimal, and the accelerated loss of β-cell by apoptosis in diabetic patients had been shown. A 40% deficit in β-cell mass was reported even in obese humans with impaired fasting glucose, which implies that the deficit in the β-cell volume is an early occurrence in the development of type 2 diabetes and is likely to be of primary importance rather than simply occurring secondary to hyperglycemia. With these results, it has been unclear, yet we could imagine that the peak β-cell mass could be determined at quite an early stage of life by genetic influences and nutritional status during the intrauterine and/or early postnatal period and progressively declined over time as a result of harmful environments during the lifetime.

**β-Cell Hypertrophy**

Recently, we observed hypertrophy of the β-cells in type 2 diabetic subjects (JH Cho, unpublished data). The average β-cell size was approximately 30% larger in type 2 diabetic patients compared with normal subjects and the ratio of cytoplasm per nucleus area was also significantly higher in diabetic subjects. As we described earlier, β-cell volume was significantly reduced in type 2 diabetic subjects. Along with this observation, we must consider the methods of β-cell volume measurements used in previous studies. The β-cell volume was assessed by the measurement of total β-cell area in islets, where each β-cell size was not considered. Therefore, the increase in each β-cell size implies that β-cell number is more reduced even in the same β-cell volume. Thus, in these cases, not only is the β-cell volume reduced, but the number of β-cells is also considerably decreased. For example, if β-cell size increased by 30% on average, in an individual with reduced β-cell mass by approximately 50%, β-cell number would actually be reduced by more than 60%. Reduced β-cell numbers can lead to more severe compensatory loading onto each β-cell, and can finally induce accelerated β-cell loss in people with type 2 diabetes. Actually, Bagust and Beale reported a model of decline in β-cell function combining two phases in which a long, slow, gradual loss of β-cell function leads to a crisis in metabolic regulation, precipitating a much more rapid decay phase. Therefore, we propose a hypothesis about morphological alterations in pancreatic islets and how β-cell loss could be more accelerated. First, factors that increase insulin resistance, such as obesity, increased calorie intake and decreased physical activity, could stimulate an increase in β-cell

---

**Figure 1** (a) The body mass index (BMI) and β-cell mass were linearly correlated in control group 1 (**r** = 0.64, **P** = 0.003) and diabetic patients (**r** = 0.55, **P** < 0.05). Remarkably, the mean value of the relative volume of β-cells in diabetic patients was lower than those of other control groups (adapted from Yoon et al). (b) The pattern of distribution of β-cells (%) among groups whose BMI ranged between 21 and 25 kg/m². The mean value of the relative volume of β-cells in diabetic patients was lower than those of other control groups (adapted from Yoon et al, Copyright 2003, The Endocrine Society).
mass through β-cell replication, β-cell neogenesis or β-cell hypertrophy, maintaining a compensatory phase and normoglycemia. However, a sustained increase in insulin demand could cause β-cell apoptosis through glucose toxicity, lipid toxicity, chronic inflammation and increased oxidative stress resulting in an uncompensated phase with reduced β-cell mass and hyperglycemia. Genetic background or intrauterine nutrition could limit β-cell expansion. Pharmacological agents, such as sulfonylurea, could play a role to increase β-cell apoptosis. An uncompensated phase could progress to an accelerating phase with severe β-cell loss over time through increased fibrosis and amyloidosis, as well as increased β-cell toxicity as described earlier. Furthermore, an increase in α-cell mass could aggravate hyperglycemia. Finally, the decline in β-cell mass caused by apoptosis and increased α-cell mass could aggravate hyperglycemia in diabetic subjects over time.

**β-Cell Proliferation vs Apoptosis**

It is also necessary to identify the factors contributing to the relatively reduced β-cell mass noted in type 2 diabetes patients. Butler *et al.* previously determined the frequency of new islet formation from exocrine ducts (neogenesis), as well as β-cell replication in islets in order to evaluate the compensatory increases in β-cell mass. There were no differences in the frequency of β-cell replication and new islet formation between type 2 diabetic and non-diabetic individuals. In our preliminary unpublished data, we observed that the contribution of the β-cell area of single β-cell units, defined as islets
composed of less than three cells and recognized as neogenetic loci\textsuperscript{15,16}, to total β-cell area tended to be greater in type 2 diabetic cases (10 ± 6%) compared with non-diabetic subjects (7 ± 5%), although there was no significant difference. These results showed that new islet formation, the predominant input into the β-cell mass in humans and β-cell replication, which was relatively low in humans, appeared to be normal or slightly increased even in type 2 diabetic patients. Therefore, we summarize that the major deficit resulting in a reduction in β-cell mass was related to increased apoptosis. Actually, the frequency of β-cell apoptosis was increased by 10-fold in the lean cases and threefold in the obese cases of type 2 diabetes, relative to their respective non-diabetic control groups\textsuperscript{10}.

**MORPHOLOGICAL ALTERATIONS OF ISLETS IN PATIENTS WITH TYPE 2 DIABETES**

Systemic morphological classification of islets is needed to understand the fate of islet over one’s lifetime. We could classify the observed islets into five different types (types 1, 2a, 2b, 3a and 3b) according to islet size and the β-cell fraction in the islet (Figure 3). Type 1 consisted of single β-cell units, defined as islets composed of less than three cells, and were recognized as neogenetic loci described earlier\textsuperscript{15,16}. Type 2 consisted of small islets (smaller than 6415 μm\textsuperscript{2}, which is the median size of islets in normal subjects\textsuperscript{11}). Type 3 consisted of large islets (larger than 6415 μm\textsuperscript{2}). An ‘a’ signified islets with normal β-cell fractions in the islets (more than 0.64, which was the value for the 75th percentile of the total islets in the control group) and a ‘b’ signified β-cell-depleted islets (<0.64). The five types of islets are shown in Figure 3. We also measured the islet size and β-cell areas of all the islets existing in the slide section randomly selected in five subjects with type 2 diabetes (DM group) and nine normal subjects (control group). From these results, we calculated the contribution rate of the β-cell area within each islet type to the total β-cell area. The results are shown in Figure 4. The contribution of the type 1 β-cell area to the total β-cell area tended to be higher in the DM group than in the control group (10.2 ± 6.0% vs 7.19 ± 4.98%, respectively), whereas the contribution of type 2a was lower in the DM group than in the control group (36.0 ± 3.51% vs 40.0 ± 11.8%, respectively). The contribution of type 3a was significantly lower in the DM group than in the control group (13.4 ± 6.7% vs 31.3 ± 14.6%, respectively; \(P = 0.025\)), whereas the contribution of type 3b was
significantly higher in the DM group than in the control group (33.9 ± 4.87% vs 17.3 ± 13.2%, respectively; P = 0.020).

INCREASED α-CELL RATIO AND MASS
Interestingly, in contrast to the changes in β-cell mass, dysregulation of glucagon secretion or the disproportionately increased number of α-cells relative to β-cells in these individuals can contribute to hyperglycemia. Müller et al. showed an unsuppressed glucagon response to a carbohydrate meal in type 2 diabetes. Unger et al. identified relative or absolute hyperglucagonemia in every form of endogeneous hyperglycemia and reported that such a glucagon excess could be a principal factor in the overproduction of glucose in diabetes. We reported that the α-cell mass was clearly increased in type 2 diabetic patients relative to the normal subjects. The ratio of α-cell area to β-cell area was far more profoundly increased in type 2 diabetic patients (Figure 5). As a mechanism of increase in α-cell mass, O’Reilly et al. previously observed α-cell neogenesis in an animal model. Ellingsgaard et al. reported that α-cell expansion was regulated by IL-6 in human islets, which is systemically elevated in obesity and is a predictive factor to developing type 2 diabetes. IL-6 was associated with α-cell proliferation and the prevention of α-cell apoptosis. We suggest α-cell neogenesis or replication also could be developed together with β-cell neogenesis or replication (Figure 2). However, it is not fully understood why α-cell mass is increased. It is also not known why increased α-cell mass is closely associated with hyperglucagonemia or unsuppressed glucagon response. So further studies on α-cell mass and dysfunction are needed.

DETERMINANT OF β-CELL MASS
Hypothesis: Thrifty Phenotype
The thrifty phenotype hypothesis proposes that there are epidemiological associations between poor intrauterine and early postnatal growth, and the subsequent development of type 2 diabetes. Since the hypothesis was proposed, many studies have confirmed the initial epidemiological evidence, although the strength of the relationships has varied from one study to another. In considering the downstream effects of poor intrauterine and early postnatal nutrition, poor development of pancreatic β-cell mass and/or function were key elements...
linking poor early nutrition to later type 2 diabetes. The hypothesis also proposed that the emergence of pathological changes after undernutrition in early life was critically dependent on the superimposition of other factors, notably obesity, aging and physical inactivity. In other words, a β-cell dysfunction induced by poor nutrition in early life period could not compensate increased insulin resistance in adult period. Whilst there is now little doubt that indices of poor early growth are linked to increased risk of type 2 diabetes, the extent to which genes or the early environment underlie the relationship remains controversial.

Genetics
Type 2 diabetes has strong genetic components. A great deal of progress has been made in our understanding of the genetics of this disease. In early studies, genetic variants in the peroxisome proliferator-activated receptor-γ gene (PPARG) and the ATP-sensitive potassium channel Kir6.2 (KCNJ11) were reproducibly associated with type 2 diabetes. In Asian populations, the protective effects of the PPARG*12A1a allele on insulin resistance and the risk of type 2 diabetes were not consistently seen. Polymorphisms in the gene encoding for transcription factor-7-like protein 2 (TCF7L2) were reported in 2006 to be associated with type 2 diabetes. This gene exerts the strongest effect on type 2 diabetes in Asian populations. However, different genetic variations in TCF7L2 are associated with type 2 diabetes in Asian populations. Several other genetic variants have been identified through genome-wide association studies, which involve the genotyping of hundreds of thousands of single-nucleotide polymorphisms on a single array. Ramachandran et al. reported that these variants are associated with type 2 diabetes in different Asian groups, including Chinese, Japanese, Korean and Indian populations. Two recent Japanese genome-wide association studies replicated several loci that had been identified previously in Europeans, and reported variants in the KCNQ1 gene that were associated with type 2 diabetes in Japanese and other east Asian populations. The majority of genetic variants that were associated with type 2 diabetes appear to be related to insulin secretion rather than to insulin resistance, and several of the risk alleles are associated with reduced β-cell function (Figure 6). Maturity Onset Diabetes of the Young (MODY) is a clinically heterogeneous group of disorders characterized by non-ketotic diabetes mellitus and a group of monogenic diabetes disorders causing 2–5% of cases of type 2 diabetes. One of these genes encodes the glycolytic enzyme glucokinase (associated with MODY 2), and the other five encode transcription factors: hepatocyte nuclear factor (HNF) 4 (associated with MODY 1), HNF-1 (MODY 3), insulin promoter factor 1 (IPF-1 [MODY 4]), HNF-1 (MODY 5) and neurogenic differentiation factor 1 (NeuroD1), also known as β-cell E-box transactivator 2 (BETA2 [MODY 6]). All these genes are expressed in β-cells, and mutation of any of them leads to β-cell dysfunction and diabetes mellitus (Figure 6). The present catalogue of type 2 diabetes risk variants most likely
accounts for only a small proportion of the genetic basis of type 2 diabetes. Nevertheless, the identification of these variants has provided us with valuable insights into the pathogenesis of type 2 diabetes.

CAUSES OF β-CELL LOSS IN ADULTS

Glucose Toxicity

The results of several studies have shown that the chronic elevation of blood glucose concentration impairs β-cell function and insulin sensitivity, a phenomenon referred to as glucotoxicity. Several mechanisms have been previously reported to increase β-cell programmed death. One common and powerful mechanism is the activation of oxidative stress as a result of increased mitochondrial generation of reactive oxygen species (ROS), a phenomenon that arises pursuant to excessive glucose metabolism. The β-cells are quite sensitive to oxidative stress, owing to very low expression and activity of anti-oxidant enzymes. Del Guerra et al. have reported that high glucose levels hamper glucose-stimulated insulin secretion, activate apoptosis, induce alterations in mitochondrial morphology and density volume, and are associated with increased intracellular nitrotyrosine content. Even glucose fluctuations, as they might arise in type 2 diabetes, might occur in the absence of the latter.

Glucolipotoxicity

The idea that neither glucose nor FFA alone cause β-cell toxicity is consistent with the ‘glucolipotoxicity’ hypothesis. In our laboratory, the glucolipotoxicity was associated with the gradual decrease in β-cell viability and increase in β-cell death in a time-dependent manner. When the islets were exposed to glucolipotoxicity, the fold increase of glucose-stimulated insulin secretion was blunted and insulin gene expression was suppressed (Figure 7). Once chronic hyperglycemia is established, it can affect pancreatic β-cell function and survival. However, elevated levels of circulating and intracellular lipids also play an important role in inducing β-cell dysfunction and decreased β-cell mass. Impaired insulin secretion in vivo coincides with major alterations in carbohydrate and lipid metabolism in β-cells. Therefore, stabilization of metabolic changes induced by glucolipotoxicity in β-cells represents a potential new avenue for the treatment of patients with type 2 diabetes mellitus. Kim et al. have reported that PGC-1α inhibits insulin and BETA2/NeuroD transcription levels and that attenuating PGC-1α overexpression protects against glucolipotoxicity-induced β-cell dysfunction. We suggest that PGC-1α plays an important key role in intracellular fuel regulation, which could herald a new era in the treatment of patients with type 2 diabetes mellitus by providing protection from glucolipotoxicity, which is an important cause of the development and progression of the disease.

Insulin Resistance in β-Cells

Insulin resistance is a common pathological state that is associated with many health disorders. Environmental and physiological stress appears to cause insulin resistance through heterologous signaling cascades. Many studies have shown a variety of factors secreted from adipose tissue that inhibit insulin signaling, FFA, tumor necrosis factor-alpha (TNF-α) and resistin, or factors that promote insulin signaling, adipocyte complement-related protein of 30 kDa (adiponectin) and leptin. A common theme to explain insulin resistance could emerge when we understand how these diverse signals interface with the insulin signaling cascade. Signaling cascades activated during acute trauma, or chronic metabolic or inflammatory stress dysregulate insulin receptor substrate (IRS) proteins through various mechanisms, including proteasome-mediated degradation, phosphatase and phosphatase and substrate (S/T-phosphorylation). Also, dysregulation of IRS protein signaling could be a common cause of peripheral insulin resistance. Furthermore, dysregulation of IRS2 in β-cells shows a mechanism of pancreatic β-cell failure that contributes to diabetes. Regardless of the complexity,
S/T-phosphorylation of IRS1 and IRS2 provides a plausible framework to understand the loss of compensatory β-cell function during progressive peripheral insulin resistance.

Amyloid Deposits and Fibrotic Destruction in the Islets of Diabetic Patients

Islet-amyloid polypeptide (IAPP), also referred to as amylin, is a normal secretory product of the pancreatic β-cells. A potential role for IAPP in the development of IR, β-cell dysfunction and type 2 diabetes has been proposed, although these studies have yielded conflicting and inconclusive results. By way of contrast with studies in which no association was detected between amyloid deposits and the duration of type 2 diabetes, others have reported an association between deposits and apoptosis, replacement of β-cell mass and declines in β-cell function.

Some investigators have concluded that up to 90% of patients with type 2 diabetes harbor amyloid deposits in their islets and that the degree of amyloidosis is correlated with the duration and severity of the disease. Human amyloid is toxic to β-cells and contributes to losses of β-cell mass. In an animal model, islet amyloidosis evidences diffuse distribution throughout the pancreas, with a progressive diminution in endocrine mass occurring in tandem with increases in amyloid mass. In other words, as the amyloid deposits expand, the β-cell mass shrinks, thus impairing β-cell function and inducing glucose intolerance.

Although amylin deposition might be the attractive primary cause of β-cell loss in diabetic patients, all the data we have so far is not yet clear.

Previously, we proposed that fibrotic islet destruction prominently observed in type 3b of Figure 3 might be one of the more important pathogenic mechanisms underlying diabetic patients’ limited β-cell proliferation capacity (Figure 2). We have determined that pancreatic stellate cells (PSC) are involved in the progression of islet fibrosis in an animal model of type 2 diabetes and, possibly, in humans suffering from type 2 diabetes. Both high concentrations of glucose and insulin in the islets contribute to PSC activation and proliferation in diabetic patients, although the exact mechanisms underlying these effects remain to be confirmed. The results of both in vitro and in vivo studies have shown that angiotensin-converting enzyme (ACE) inhibitor (ACEi) attenuates the islet destruction caused by fibrosis, and that this attenuation exerts some beneficial effects on glucose tolerance by suppressing the activation and proliferation of PSC.
of PSC. We suggest that PSC might play an important role in the pathogenesis of fibrotic islet destruction observed in conjunction with type 2 diabetes.

**Chronic Inflammation as a Cause of β-Cell Loss**

Schuster recently reported that the ability to store and limit fatty acid deposition to adipose tissue is a key component in remaining insulin sensitive, controlling the inflammatory cascade and reducing the risk of developing obesity-related comorbidities, such as DM. The pancreatic islet could also be a target of inflammation. Inflammation in a tissue is classically defined by tissue damage, impaired function, the presence of increased numbers of immune cells and/or activation of local tissue immune cells, and local production of cytokines and chemokines. An accumulating body of evidence also indicates that this is the case in the human pancreatic islet in type 2 diabetes. The β-cells of patients with type 2 diabetes express elevated levels of IL-1β and a variety of chemokines. Based on tissue histology, islets from type 2 diabetes patients express increased amounts of IL-1β, increased caspase-1 (required for the cleavage of proIL-1β) to active IL-1β and reduced amounts of IL-1Ra (the IL-1 receptor antagonist) and are infiltrated with macrophages. Thus, an islet inflammation might be involved in β-cell compensation for insulin resistance, but if the inflammation were chronic, β-cell demise would be the expected result.

**Sulfonylurea**

Glibenclamide and chlorpropamide treatment have been associated with improvements in glycemic control and lower incidence of microangiopathic complications. Nonetheless, as mentioned previously, improvements in glycemic control were associated with an initial increase of the HOMA-B, an index of β-cell function, followed by a progressive linear decline. Losses of β-cell mass and function have raised concerns regarding the use of sulfonylureas for the treatment of type 2 diabetes. The results of some previous animal and cell studies have shown that these agents might induce β-cell apoptosis. Studies carried out in isolated human islets suggest that glibenclamide, but not repaglinide, might activate apoptosis in β-cells. Nateglinide at low concentrations was not observed to induce β-cell apoptosis. The incubation of pancreatic islets and β-cell cells from ob/ob mice and Wistar rats with glucose and sulfonylureas has also been show to induce apoptotic β-cell death. Therefore, the loss of β-cell function was determined to not be unique to sulfonylureas, as it occurred at an identical rate in patients treated with metformin or conventional treatments, thus suggesting that factors other than treatment might contribute to the process.

**DISCUSSION**

The impact of a reduction in β-cell mass in terms of the alterations of insulin secretion that characterize type 2 diabetes has yet to be clearly elucidated. Still, clinical observations and experimental data support a close interrelationship between the two parameters. Thus, a large proportion of living, related pancreatic donors who underwent a 50% pancreatectomy ultimately developed diabetes. Pharmacological or surgical reduction of β-cell mass in rodents has been shown to uniformly impair insulin secretion. More recently, Matveyenko et al. have carefully analyzed the effects of a 50% pancreatectomy in normal dogs, and reported that partial pancreatectomy resulted in IGF and IGT. Partial pancreatic resection was associated with reductions of both basal and glucose-stimulated insulin secretion. Collectively, these data support a mechanistic role of reduced β-cell mass in the development of alterations in glucose homeostasis and progression toward type 2 diabetes. Actually, many authors have noted reduced β-cell mass in human patients suffering from type 2 diabetes. Additionally, such reductions in β-cell mass are strongly associated with increased β-cell apoptosis, whereas new islet formation rates and β-cell replication remain relatively normal. Furthermore, the results of our recent study regarding β-cell size in humans with type 2 diabetes showed that the β-cells in these patients were approximately 30% larger than the β-cells of normal subjects. The ratio of cytoplasmic area to nuclear area was also far higher in the type 2 diabetic patients relative to normal controls. Most studies on β-cell mass in humans with type 2 diabetes have been based on measurements of the total β-cell area in the islets. Thus, considering that β-cell size itself was also increased, we surmised that the numbers of β-cells were even lower in the type 2 diabetic subjects than had been estimated. Reduced β-cell mass, which includes decreased β-cell numbers, might exacerbate disease burdens and aggravate β-cell loss, causing continuous progression of the disease state. Several genetic factors and acquired factors, such as glucose toxicity, lipid toxicity, inflammation and exogenous stimuli, have been shown to cause β-cell defects. Thus, in order to develop more fundamental treatments for type 2 diabetes, more advanced approaches focusing on the β-cells themselves in order to directly prevent damage or restore functional defects must be developed, along with efforts to minimize or ameliorate acquired conditions, such as increases in insulin resistance, glucotoxicity, lipidotoxicity and exogenous factors relevant to β-cell injury. Additionally, greater efforts must be made in the future to gain insight into alterations and disruptions of the microenvironment in the pancreatic islets of type 2 diabetic subjects, and to find ways of improving that environment in order to minimize such disruptions.

**ACKNOWLEDGEMENTS**

This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (A092258).

**REFERENCES**

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782–787.
2. Gu D, Reynolds K, Duan X, et al. Prevalence of diabetes and impaired fasting glucose in the Chinese adult population:
International Collaborative Study of Cardiovascular Disease in Asia (Interasia). Diabetologia 2003; 46: 1190–1198.

3. Ramachandran A. Epidemiology of diabetes in India – three decades of research. J Assoc Physicians India 2005; 53: 34–38.

4. Yoon KH, Lee JH, Cho JH, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006; 368: 681–688.

5. Kahn SE. The relative contribution of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3–19.

6. Ferrannini E, Mari A. Beta-cell function and its relation to insulin action in humans: a critical appraisal. Diabetologia 2004; 47: 943–956.

7. Saito K, Yaginuma N, Takahashi T. Differential vometry of A, B and D cells in the pancreatic islets of diabetic and non-diabetic subjects. Tohoku J Exp Med 1979; 129: 273–283.

8. Westermark P, Wilander E. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 1978; 15: 417–421.

9. Sakuraba H, Mizukami H, Yagihashi N, et al. Reduced beta-cell mass and expression of oxidative-stress-related DNA damage in the islets of Japanese type 2 diabetic patients. Diabetologia 2002; 45: 86–96.

10. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102–110.

11. Yoon KH, Ko SH, Cho JH, et al. Selective beta cell loss and alpha cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 2003; 88: 2300–2308.

12. Rahier J, Guiot Y, Goebbels RM, et al. Pancreatic beta-cell mass in European subjects with type 2 diabetes: a long-term model. Diabetes Care 2003; 26: 3–19.

13. Bouwens L. Transdifferentiation versus stem cell hypothesis for the regeneration of islet beta-cells in the pancreas. Microsc Res Tech 1998; 49: 332–336.

14. Müller WA, Faloon GR, Aguilar-Parada E, et al. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1976; 283: 109–115.

15. Unger RH, Orsi L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1975; 1: 14–16.

16. Deng S, Vatamaniuk M, Huang X, et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 2004; 53: 624–632.

17. Donath MY, Ehses JA, Maedler K, et al. Mechanisms of beta-cell death in type 2 diabetes. Diabetes 2005; 54(Suppl 2): S108–S113. Review.

18. Rahier J, Goebbels RM, Henquin JC. Cellular composition of the human diabetic pancreas. Diabetologia 1983; 24: 366–371.

19. Gromada J, Franklin I, Wollheim CB. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 2007; 28: 84–116. Epub 2007 Jan 16.

20. O'Reilly LA, Gu D, Sarvetnick N, et al. Alpha cell neogenesis in animal model of IDDM. Diabetes 1997; 46: 599–606.

21. Ellingsgaard H, Ehses JA, Hammar MB, et al. Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci USA 2008; 105: 13163–13168. Epub 2008 Aug 21.

22. Hales CN, Barker DJP. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 1992; 35: 595–601.

23. Hales CN, Barker DJP, Clark PMS, et al. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ 1991; 303: 1019–1022.

24. Barker DJP, Hales CN, Fall CHD, et al. The contribution of fetal growth and impaired glucose tolerance at age 64. BMJ 1991; 303: 1019–1022.

25. Altmüller D, Hirschhorn JN, Klammemark M, et al. The common PPAR gamma Pro12 Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26: 76–80.

26. Gloyn AL, Weedon MN, Owen KR, et al. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 2003; 52: 568–572.

27. Radha V, Vimalakumar KS, Babu NH, et al. Role of genetic polymorphism peroxisome proliferators-activated receptor-gamma2 Pro12Ala on ethnic susceptibility to diabetes in the Chinese population. Diabetes Med 2006; 23: 940–947.

28. Altmüller D, Hirschhorn JN, Klammemark M, et al. The common PPAR gamma Pro12 Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26: 76–80.

29. Altmüller D, Hirschhorn JN, Klammemark M, et al. The common PPAR gamma Pro12 Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26: 76–80.
37. Unoki H, Takahashi A, Kawaguchi T, et al. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet 2008; 40: 1098–1102.

38. Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007; 117: 2155–2163.

39. Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008; 359: 2220–2232.

40. Frayling TM. Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet 2007; 8: 657–662.

41. Florez JC. Clinical review: the genetics of type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 4633–4642.

42. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001; 345: 971–980.

43. Froquel P, Zouali H, Vionnet N, et al. Familial hyperglycemia due to mutations in glucokinase: definition of a subtype of diabetes mellitus. N Engl J Med 1993; 328: 697–702.

44. Yagamata K, Furuta H, Oda N, et al. Mutations in the hepatocyte nuclear factor-4 gene in maturity-onset diabetes of the young (MODY1). Nature 1996; 384: 458–460.

45. Yamagata K, Oda N, Kaisaki PJ, et al. Mutations in the hepatocyte nuclear factor-1 gene in maturity-onset diabetes of the young (MODY3). Nature 1996; 384: 455–458.

46. Stofflers DA, Ferrer J, Clarke WL, et al. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet 1997; 17: 138–139.

47. Horikawa Y, Iwasaki N, Harra M, et al. Mutation in hepatocyte nuclear factor-1 gene (TCF2) associated with MODY. Nat Genet 1997; 17: 384–385.

48. Malecki MT, Jhala US, Antonellis A, et al. Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nat Genet 1999; 23: 323–328.

49. Kaiser N, Leibowitz G, Nesher R. Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2003; 16: 5–22.

50. Robertson RP, Harmon J, Tran PO, et al. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the gluthione connection. Diabetes 2003; 52: 581–587.

51. Zraika S, Aston-Mourney K, Laybutt DR, et al. The influence of genetic background on the induction of oxidative stress and impaired insulin secretion in mouse islets. Diabetes 2006; 49: 1254–1263.

52. Del Guerra S, Grupillo M, Masini M, et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes Metab Res Rev 2007; 23: 234–238.

53. Harding HP, Ron D. Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes 2002; 51: S455–S461.

54. Schroder M, Kaufman RJ. ER stress and the unfolded protein response. Mutat Res 2005; 569: 29–63.

55. Rabinovitch A, Suarez-Pinzon WL. Roles of cytokines in the pathogenesis and therapy of type 1 diabetes. Cell Biochem Biophys 2007; 48: 159–163.

56. Marchetti P, Bugliani M, Lupi R, et al. The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. Diabetologia 2007; 50: 2486–2494.

57. Maeder KL, Oberholzer J, Bucher P, et al. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes 2003; 52: 726–733.

58. Lupi R, Dotta F, Marselli L, et al. Prolonged exposure to free fatty acids has cytoprotective and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 2002; 51: 1437–1442.

59. Wrede CE, Dickson LM, Lingohr MK, et al. Protein kinase B/Akt prevents fatty acid-induced apoptosis in pancreatic beta-cells (INS-1). J Biol Chem 2002; 277: 49676–49684.

60. Shimabukuro M, Zhou YT, Levi M, et al. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 1998; 95: 2498–2502.

61. Shimabukuro M, Ohneda M, Lee Y, et al. Role of nitric oxide in obesity induced beta cell disease. J Clin Invest 1997; 100: 290–295.

62. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 2008; 29: 351–366.

63. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006; 116: 1802–1812.

64. Laybutt DR, Kaneto H, Hasenkamp W, et al. Increased expression of antioxidant and antiapoptotic genes in islets that may contribute to beta-cell survival during chronic hyperglycemia. Diabetes 2002; 51: 413–423.

65. Pick A, Clark C, Kubstrup M, et al. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 1998; 47: 358–364.

66. Prentki M, Joly E, Al-Assaad W, et al. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes 2002; 51: S405–S413.

67. Kim JW, You YH, Harn DS, et al. Suppression of peroxisome proliferator-activated receptor gamma-coactivator-1alpha normalizes the glucolipotoxicity-induced decreased BETA2/NeuroD gene transcription and improved glucose tolerance in diabetic rats. Endocrinology 2009; 150: 4074–4083.

68. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 9467: 1333–1346.

69. White MF. Insulin signaling in health and disease. Science 2003; 3051: 1710–1711.

70. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 5091: 87–91.
Morphological alterations of islets

71. Schmitz-Peiffer C, Whitehead JP. IRS-1 regulation in health and disease. IUBMB Life 2003; 55: 367–374.

72. Lin X, Taguchi A, Park S, et al. Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. J Clin Invest 2004; 114: 908–916.

73. Kahn SE, Verchere CB, Andrikopoulos S, et al. Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 1998; 47: 640–645.

74. Leighton B, Cooper CJS. Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vivo. Nature 1988; 335: 632–635.

75. Silvestre RA, Peiró E, Dégano P, et al. Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas. Regul Pept 1990; 31: 23–31.

76. Cooper GJS, Day AJ, Willis AC, et al. Amylin and the amylin gene: structure, function and relationship to islet amyloid and to diabetes mellitus. Biochem Biophys Acta 1989; 1014: 247–258.

77. Sempoux C, Guiot Y, Dubois D, et al. Human type 2 diabetes: morphological evidence for abnormal beta-cell function. Diabetes 2001; 50: S172–S177.

78. Bernard-Kargar C, Ktorza A. Endocrine pancreas plasticity: morphological evidence for abnormal beta-cell function. Diabetes Metab Res Rev 2001; 17: 181–188.

79. Kahn SE, Verchere CB, Andrikopoulos S, et al. Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 1998; 47: 640–645.

80. Kahn SE, Verchere CB, Andrikopoulos S, et al. Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 1998; 47: 640–645.

81. Finegood D, Topp B. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 1999; 48: 241–253.

82. Hayden M, Tyagi S. Islet redox stress: the manifold toxicities of insulin resistance, metabolic syndrome and amylin derived islet amyloid in type 2 diabetes mellitus. Pancreas 2002; 3: 86–108.

83. Janson J, Ashley R, Harrison D, et al. The mechanism of islet amyloid poly pep tide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 1999; 48: 491–498.

84. Lorenzo A, Razzaboni B, Weir GC, et al. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994; 368: 756–760.

85. Wang F, Hull R, Vidal J, et al. Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes 2001; 50: 2514–2520.

86. Kim JW, Ko SH, Cho JH, et al. Loss of beta-cells with fibrotic islet destruction in type 2 diabetes mellitus. Front Biosci 2008; 13: 6022–6033.

87. Ko SH, Hong OK, Kim JW, et al. High glucose increases extracellular matrix production in pancreatic stellate cells by activating the renin-angiotensin system. J Cell Biochem 2006; 98: 343–355.

88. Schuster DP. Obesity and the development of type 2 diabetes: the effects of fatty tissue inflammation. Diabetes Metab Syndr Obes 2010; 3: 253–262.

89. Marselli L, Sgroi DC, Thorne J, et al. Evidence of inflammatory markers in beta cells of type 2 diabetic subjects. Diabetologia 2007; 50: S178.

90. Maedler K, Sergeev P, Rs F, et al. Glucoseinduced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851–860.

91. Maedler K, Schulthess FT, Bielman C, et al. Glucose and leptin induce apoptosis in human beta-cells and impair glucose stimulated insulin secretion through activation of c-Jun N-terminal kinases. FASEB J 2008; 22: 1905–1913.

92. Maedler K, Sergeev P, Ehses JA, et al. Leptin modulates beta-cell expression of the IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Nat Acad Sci U S A 2004; 101: 8138–8143.

93. Ehses JA, Perren A, Eppler E, et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007; 56: 2356–2370.

94. Richardson SJ, Willcox A, Bone AJ, et al. Islet-associated macrophages in type 2 diabetes. Diabetologia 2009; 52: 1686–1688.

95. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.

96. Heald AH, Anderson SG, Patel J, et al. Change in pancreatic B-cell function (HOMA-B) varies in different populations with similar genetic backgrounds but different environments. Diabet Med 2007; 24: 145–153.

97. Maedler K, Carr RD, Bosco D, et al. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005; 90: 501–506.

98. Efanovala IB, Zaitsev SV, Zhivotovsky B, et al. Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. J Biol Chem 1998; 273: 33501–33507.

99. Kendall DM, Sutherland DE, Najarian JS, et al. Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans. N Engl J Med 1990; 322: 898–903.

100. Weir GC, Leahy JL, Bonner-Weir S. Experimental reduction of B-cell mass: implications for the pathogenesis of diabetes. Diabetes Metab Rev 1986; 2: 125–161.

101. Matveyenko AV, Veldhuis JD, Butler PC. Mechanisms of impaired fasting glucose and glucose intolerance induced by an approximate 50% pancreatectomy. Diabetes 2006; 55: 2347–2356.